Modified Wuzi Yanzong Prescription Inhibited Tau Protein Hyperphosphorylation induced by Aβ25-35-in PC12 Cells

ZENG Ke-wu,WANG Xue-mei,FU Hong,LIU Geng-xin
DOI: https://doi.org/10.3969/j.issn.1005-9903.2011.09.046
2011-01-01
Abstract:Objective:To investigate the neuroprotective effect of modified Wuzi Yanzong prescription(MWP)on β-amyloid protein(Aβ25-35)-induced tau protein hyperphosphorylation in PC12 cells and the potential mechanism.Method: Control,Aβ25-35 model and sample treatment groups were set in our study.Aβ25-35(30 μmol.L-1)was used to induce tau protein hyperphosphorylation in PC12 cells,and MWP(50-400 mg.L-1) was also simultaneously added.Then,the neuroprotective effects of MWP were investigated.Result: MWP alone did not show any cytotoxicity in PC12 cells.MWP significantly protected PC12 cells from Aβ25-35-induced neurotoxicity,cellviability increased from(70 ± 4.9)% to(98 ± 6.5)%(P < 0.01),and apoptosis-related protein(Caspase-3 and PARP) expressions were also effectively inhibited,Caspase-3 and PARP were down-regulated from(378.15 ±34.65)% and(985.12 ± 45.32)% to(127.65 ± 12.65)% and(543.61 ± 39.07)%(P < 0.01).In addition,tau protein hyperphosphorylation in PC12 cells was significantly down-regulated,p-tau(in Ser396 site) expression decreased from(130.01 ± 5.83)% to(113.75 ± 6.34)%(P < 0.01),and p-tau(in Ser404 site) expression decreased from(150.17 ± 10.28)% to(105.37 ± 4.57)%(P < 0.01).The inhibitory effects of MWP on the phosphorylation of glycogen synthase kinase 3β(GSK-3β) at Ser9 site and mitogen-activated protein kinases (MAPK) may explain the potential mechanism.Conclusion: MWP could inhibit Aβ25-35-induced tau protein hyperphosphorylation on PC12 cells,showing a neuroprotective effect in Alzheimer’s disease.
What problem does this paper attempt to address?